SCHEMBL3229877

SCHEMBL3229877

CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)OCC)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.84
AGTR1 P30556 4/20 0.84
AGTR2 P50052 3/20 0.84
KDM4E B2RXH2 1/20 0.84
ABCC3 O15438 1/20 0.84
ABCC4 O15439 1/20 0.84
USP2 O75604 1/20 0.84
ABCB11 O95342 1/20 0.84
ALDH1A1 P00352 1/20 0.84
CHRM2 P08172 1/20 0.84
CYP3A4 P08684 1/20 0.84
ADRA2A P08913 1/20 0.84
ADORA3 P0DMS8 1/20 0.84
CHRM1 P11229 1/20 0.84
CYP2C9 P11712 1/20 0.84
ACE P12821 1/20 0.84
ADRA2C P18825 1/20 0.84
TBXA2R P21731 1/20 0.84
GLRA1 P23415 1/20 0.84
PDE4A P27815 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19432748 0.95 PPARG (0.81) PPARGAGTR1AGTR2KDM4EABCC3
SCHEMBL255337 0.94 AGTR1 (0.84) PPARGAGTR1AGTR2KDM4EABCC3
Hydrochloric Acid SCHEMBL1203765 0.93 PPARG (0.78) PPARGAGTR1AGTR2KDM4EABCC3
SCHEMBL17948609 0.93 PPARG (0.84) PPARGAGTR1AGTR2KDM4EABCC3
SCHEMBL10021554 0.92 AGTR1 (0.80) PPARGAGTR1AGTR2KDM4EABCC3
SCHEMBL170874 0.92 PPARG (0.80) PPARGAGTR1AGTR2KDM4EABCC3
SCHEMBL13138015 0.91 PPARG (0.88) PPARGAGTR1AGTR2KDM4EABCC3
SCHEMBL17946015 0.91 PPARG (0.88) PPARGAGTR1AGTR2KDM4EABCC3
Telmisartan SCHEMBL2122886 0.91 AGTR1 (1.00) PPARGAGTR1AGTR2KDM4EABCC3
Telmisartan SCHEMBL4464 0.91 AGTR1 (1.00) PPARGAGTR1AGTR2KDM4EABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598202-B2 Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA NV (BE) 2013-12-03 US claimed
EP-2254415-B1 ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2013-01-23 EP claimed
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2009-10-22 US claimed
US-8598202-B2 Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA NV (BE) 2013-12-03 US disclosed
EP-2254415-B1 ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2013-01-23 EP disclosed
EP-1719766-B1 A process for the preparation of telmisartan DIPHARMA FRANCIS SRL (IT) 2010-11-03 EP disclosed
US-7692027-B2 Process for the preparation of telmisartan DIPHARMA S.P.A. (IT) 2010-04-06 US disclosed
WO-2010018441-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE TELMISARTAN CADILA PHARMACEUTICALS LTD. (IN) 2010-02-18 WO disclosed
EP-2123648-A1 A process for the preparation of Telmisartan. Chemo Ibérica, S.A. (ES) 2009-11-25 EP disclosed
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2009-10-22 US disclosed
US-20060264644-A1 Process for the preparation of telmisartan DIPHARMA S.P.A. (IT) 2006-11-23 US disclosed
EP-1719766-A2 A process for the preparation of telmisartan Dipharma S.p.A. (IT) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264429-A1 Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase FAAH, FAAH2, HRH2 PPARG 115/4885AGTR1 2561/4885AGTR2 2246/4885
US-20060264644-A1 Process for the preparation of telmisartan AGT, REN, AGTR1 PPARG 2556/4885AGTR1 3/4885AGTR2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.